{"classes":[{"categories":[{"measurements":[{"comment":"95% CI not determined due to few surviving patients.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Percentage of patients alive at 24 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial.\n\nBiospecimen Collection: Undergo blood sample collection\n\nCabozantinib S-malate: Given PO\n\nComputed Tomography: Undergo CT\n\nMagnetic Resonance Imaging: Undergo MRI\n\nNivolumab: Given IV","id":"OG000","title":"Treatment (Cabozantinib S-malate, Nivolumab)"}],"paramType":"NUMBER","populationDescription":"All enrolled patients","reportingStatus":"POSTED","timeFrame":"At 24 months","title":"24-month Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}